News & Events

(SEATTLE), April 23, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with AdaptVac to develop and produce a COVID-19 vaccine. AdaptVac, together with its EU Horizon 2020 sponsored PREVENT-nCoV consortium partners, are developing a SARS-CoV-2 vaccine. The COVID-19 pandemic is still evolving, and AdaptVac’s Virus-Like Particle (VLP) technology could provide a solution to protect against new SARS-CoV-2 infections.

AGC Biologics Sponsors 14th Annual BIO-Europe Spring Conference

For 2020, the BIO International Convention  will transition to a new, virtual event format, BIO Digital.  This virtual gathering of the global biotech industry provides access to key partners via BIO one-on-one partnering, education resources to help drive your business, and the insights you need to continue critical research and development. 

We may not be able to gather in person, but nothing stops innovation.

If you would like to set up a meeting, please email us at info@agcbio.com to set up a meeting or contact us via our website http://agcbio.com/contactus

Engage with AGC Biologics at Europe's largest fall biotech partnering event.  Email us at info@agcbio.com to set up a meeting or contact us via our website https:  www.agcbio.com/contact_us/.

We're looking forward to attending MIXiii BIOMED in Tel Aviv, Israel.  Will you be joining us there?  If you would like to set up a meeting, please email us at info@agcbio.com or contact us via our website http://agcbio.com/contactus

This year's event in Tel Aviv will expand the scope and range of topics to explore trends and innovations which are shaping the future of the healthcare system to its full extent.  It will discuss prevention, diagnosis, monitoring and treatment domains, emphasizing quality of life extension.  In all topics they will feature Medical Device, Biopharma, Digital Health and Diagnosis where appropriate.

Learn More

Engage with AGC Biologics at Europe's largest fall biotech partnering event.  Email us at info@agcbio.com to set up a meeting or contact us via our website http://www.agcbio.com/contact us/. 

This year's event in Munich will bring together the "who's who" from the biotech, pharma and finance segments to allow delegates to meet more key decision makers in three days of partnering meetings than they could in a whole year. Learn More

Seattle CBS affiliate KIRO visited our Bothell, Washington headquarters to interview AGC Biologics CEO Patricio Massera and Chief Business Officer Mark Womack about the work we’re doing with partner CytoDyn. CytoDyn scientists discovered that HIV drug leronlimab could potentially work to treat COVID-19. AGC Biologics is producing a key molecule for the drug.

AGC Biologics fosters strong customer partnerships by conducting virtual meetings

Tokyo, March 17, 2020 – AGC Inc., (Headquarters: Tokyo; President & CEO: Takuya Shimamura) has decided to launch a voluntary tender offer (“VTO”) to acquire all ordinary shares of Molecular Medicine S.p.A. (“Molmed”) a company with shares listed on the Italian Stock Exchange (Milan) pursuant to article 102, first paragraph, of the Italy Legislative Decree No. 58 of 24 February 1998 and related regulations. Molmed is a clinical stage biotechnology company focused on research, development, manufacturing and clinical validation of gene & cell therapies, and offers GMP services for the development and manufacturing of gene & cell therapies for third parties and/or in partnership at its authorized facilities (“CDMO Services”^*1).